Moderated Poster Session: Trauma And Reconstruction Reported From The Annual bi13250980 ORLANDO, FL (UroToday.com) - The first session trauma and reconstruction took place Saturday, May 17, 2008 and was moderated by Michael Coburn and Leonard Zinman. It consisted of 20 abstracts on topics ranging from urethral reconstruction, management of rectourethral fistula, renal trauma, management of the buried penis, and vaginal reconstruction

Positive Phase III Data Unveiled For New GnRH Blocker Degarelix - Degarelix S bi13250980 Data from a Phase III study demonstrated that the investigational GnRH blocker, degarelix, produced a significant reduction levels of testosterone , three days more than 96% of study patients2 was discussed during the Late Breaking Science Forum at the 2008 Annual Meeting of the American Urological Association (AUA)

Pediatrics: Basic Research (MP #21) Reported From The Annual Meeting Of The A bi13250980 ORLANDO, FL (UroToday.com) - Selected Abstracts Moderated Session 21: May 19, 2008 8:00 AM. Abstract 622: The ureteric bud appears to be bidirectional growth according to Wnt/Î²-catenin signaling. Abstract 626: Social stress causes dysfunctional voiding mice. The submissive mouse when exposed to an aggressive mouse retain urine and change voiding pattern

Two-Year Clinical Trial Findings Show Significant and Persistent Reduction in bi13250980 The first available two-year data from the European clinical trial evaluating the Rheos(R) Hypertension (HT) System were presented today at Hypertension Berlin 2008. Developed by U.S.-based CVRx, Inc., the Rheos HT System the only implantable medical device designed to control hypertension, or high blood pressure. Worldwide, hypertension a leading and growing cause of heart and kidney ..

Two-Year Clinical Trial Findings Show Significant and Persistent Reduction in bi13250980 MINNEAPOLIS & BERLIN----The first available two-year data from the European clinical trial evaluating the Rheos® Hypertension System were presented today at Hypertension Berlin 2008

My Pharmiweb.com (PharmiWeb) bi13250980 Basel, June 17, 2008 ? Novartis today announced details of two new long-term outcome studies landmark ASPIRE HIGHER clinical trial program has expanded to involve more than 35,000 patients 14 trials

17.06.2008 - DJ HUGIN NEWS/Rasilez®[*] ASPIRE HIGHER clinical program expands bi13250980 Corporate news announcement processed and transmitted by Hugin ASA. The issuer solely responsible for the content of announcement. =--------------------------------------------------------------------- =------------- * Novartis to study organ protection potential of Rasilez beyond documented ability to provide powerful blood pressure reductions that last beyond 24 hours[1],[2] * Three ..

DJ HUGIN NEWS/Rasilez®[*] ASPIRE HIGHER clinical -2- (Financial.de) bi13250980 Corporate news announcement processed and transmitted by Hugin ASA. The issuer solely responsible for the content of announcement

Maximus Features MaxPlus Clear(R) and New Clinical Research at Association fo bi13250980 Maximus, a business unit of leading infusion therapy firm Medegen Inc., exhibit at the Association for Professionals Infection Control and Epidemiology (APIC) annual scientific conference, June 15-17 Denver, Colorado. The exhibit feature the new MaxPlus(R) Clear, the first and only clear positive displacement connector for use patient care, as well as two award-winning ..

Pediatrics: Trauma/Tumors/Stone Disease & Infection/Imaging (Pos #39) - Annua bi13250980 ORLANDO, FL (UroToday.com) - Selected Abstracts Moderated Session 39: May 19, 2008 3:30 PMAbstract 1108: metabolic abnormalities were seen at a similar rate between younger and older patients. However, children under 10 years of age were more likely to pass a stone than older ones. The mean stone size was 2.75mm for the groups

Positive Phase III Data Unveiled For New GnRH Blocker Degarelix - Degarelix S bi13250980 Data from a Phase III study demonstrated that the investigational GnRH blocker, degarelix, produced a significant reduction levels of testosterone , three days more than 96% of study patients2 was discussed during the Late Breaking Science Forum at the 2008 Annual Meeting of the American Urological Association (AUA)

Pediatrics: Basic Research (MP #21) Reported From The Annual Meeting Of The A bi13250980 ORLANDO, FL (UroToday.com) - Selected Abstracts Moderated Session 21: May 19, 2008 8:00 AM. Abstract 622: The ureteric bud appears to be bidirectional growth according to Wnt/Î²-catenin signaling. Abstract 626: Social stress causes dysfunctional voiding mice. The submissive mouse when exposed to an aggressive mouse retain urine and change voiding pattern

Adult Babies Wearing Diapers - Home